FY2023 · ended Dec 31, 2023 · Revenue $675,000, -29.0% YoY · Filed Mar 31, 2025
Unicycive Therapeutics, Inc. (UNCY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$31.3 million. As of Jun 30, 2026 it held $61.4 million in cash and investments and $671,000 in total debt.
Revenue
$675,000
-29.0% vs prior year
Net income
$-26.55M
+27.7% vs prior year
Operating cash flow (TTM)
$-27.84M
+16.0% vs year-ago TTM
Free cash flow (TTM)
$-27.85M
+16.1% vs year-ago TTM
EPS
$-1.67
+70.4% vs prior year
Dividend per share
None
Shares outstanding
25.24M
-78.9% vs prior year
Net cash
$60.75M
as of Jun 30, 2026
Operating margin
-3077.6%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UNCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1766140
- Former names
- Unicycive Therapeutics, Inc. (until Oct 29, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $675,000 | $951,000 | — |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M |
| Diluted EPS | -$1.67 | -$5.65 | -$1.28 | -$1.20 | — |
| Operating cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Free cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | — |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M |
| Stockholders' equity | $30.2M | $7.4M | -$3.8M | -$466,000 | $16.5M |
| Cash and investments | $41.3M | — | — | $455,000 | $16.6M |
| Total debt | $117,000 | $681,000 | $793,000 | $155,000 | $306,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 19, 2026 |
All 307 Unicycive Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.